CMR Surgical Limited, headquartered in the United Kingdom, is a pioneering company in the field of surgical robotics. Founded in 2014, CMR has rapidly established itself as a leader in the medical technology industry, focusing on the development of innovative robotic-assisted surgical systems. The company’s flagship product, the Versius® Surgical Robotic System, is designed to enhance minimally invasive surgery, offering surgeons greater precision and flexibility. CMR's commitment to advancing surgical techniques has positioned it as a key player in the global market, with significant operational presence across Europe and beyond. Notable achievements include securing substantial funding to support research and development, as well as partnerships with leading healthcare institutions. CMR Surgical continues to drive innovation, aiming to transform surgical practices and improve patient outcomes worldwide.
How does CMR Surgical Limited's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
CMR Surgical Limited's score of 49 is higher than 70% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, CMR Surgical Limited reported total carbon emissions of approximately 105,045,000 kg CO2e. This includes Scope 1 emissions of about 25,501,000 kg CO2e, Scope 2 emissions of approximately 69,818,000 kg CO2e (market-based), and a significant Scope 3 total of around 805,038,000 kg CO2e. The Scope 3 emissions breakdown reveals substantial contributions from purchased goods and services (approximately 294,280,000 kg CO2e) and waste generated in operations (about 155,306,000 kg CO2e). For 2023, the company recorded Scope 1 emissions of about 26,828,000 kg CO2e and Scope 2 emissions of approximately 78,217,000 kg CO2e (market-based). In 2022, CMR Surgical's emissions included around 4,007,860 kg CO2e for Scope 1, 616,660 kg CO2e for Scope 2, and 5,443,490 kg CO2e for Scope 3. The 2021 figures showed Scope 1 emissions of about 4,795,340 kg CO2e, Scope 2 emissions of approximately 3,031,960 kg CO2e, and Scope 3 emissions of around 3,518,520 kg CO2e. CMR Surgical has set ambitious climate commitments, aiming to reduce Scope 1 emissions to near zero by 2025 and to cut Scope 2 emissions by 30% from a 2021 baseline by 2030. These targets reflect the company's commitment to sustainability and align with industry standards for carbon reduction.
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 4,795,340 | 0,000,000 | 00,000,000 | 00,000,000 | 
| Scope 2 | 3,031,960 | 000,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | 3,518,520 | 0,000,000 | - | 000,000,000 | 
CMR Surgical Limited's Scope 3 emissions, which increased significantly last year and increased significantly since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 37% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
CMR Surgical Limited has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
